Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database.

Dominguez-Valentin M, Sampson JR, Seppälä TT, Ten Broeke SW, Plazzer JP, Nakken S, Engel C, Aretz S, Jenkins MA, Sunde L, Bernstein I, Capella G, Balaguer F, Thomas H, Evans DG, Burn J, Greenblatt M, Hovig E, de Vos Tot Nederveen Cappel WH, Sijmons RH, Bertario L, Tibiletti MG, Cavestro GM, Lindblom A, Della Valle A, Lopez-Köstner F, Gluck N, Katz LH, Heinimann K, Vaccaro CA, Büttner R, Görgens H, Holinski-Feder E, Morak M, Holzapfel S, Hüneburg R, Knebel Doeberitz MV, Loeffler M, Rahner N, Schackert HK, Steinke-Lange V, Schmiegel W, Vangala D, Pylvänäinen K, Renkonen-Sinisalo L, Hopper JL, Win AK, Haile RW, Lindor NM, Gallinger S, Le Marchand L, Newcomb PA, Figueiredo JC, Thibodeau SN, Wadt K, Therkildsen C, Okkels H, Ketabi Z, Moreira L, Sánchez A, Serra-Burriel M, Pineda M, Navarro M, Blanco I, Green K, Lalloo F, Crosbie EJ, Hill J, Denton OG, Frayling IM, Rødland EA, Vasen H, Mints M, Neffa F, Esperon P, Alvarez K, Kariv R, Rosner G, Pinero TA, Gonzalez ML, Kalfayan P, Tjandra D, Winship IM, Macrae F, Möslein G, Mecklin JP, Nielsen M, Møller P.

Genet Med. 2019 Jul 24. doi: 10.1038/s41436-019-0596-9. [Epub ahead of print]

PMID:
31337882
2.

Causes for Frequent Pathogenic BRCA1 Variants Include Low Penetrance in Fertile Ages, Recurrent De-Novo Mutations and Genetic Drift.

Møller P, Dominguez-Valentin M, Rødland EA, Hovig E.

Cancers (Basel). 2019 Jan 23;11(2). pii: E132. doi: 10.3390/cancers11020132.

3.

Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases.

Østrup O, Dagenborg VJ, Rødland EA, Skarpeteig V, Silwal-Pandit L, Grzyb K, Berstad AE, Fretland ÅA, Mælandsmo GM, Børresen-Dale AL, Ree AH, Edwin B, Nygaard V, Flatmark K.

Oncotarget. 2017 Jul 18;8(44):76290-76304. doi: 10.18632/oncotarget.19350. eCollection 2017 Sep 29.

4.

Colorectal cancer incidence in path_MLH1 carriers subjected to different follow-up protocols: a Prospective Lynch Syndrome Database report.

Seppälä T, Pylvänäinen K, Evans DG, Järvinen H, Renkonen-Sinisalo L, Bernstein I, Holinski-Feder E, Sala P, Lindblom A, Macrae F, Blanco I, Sijmons R, Jeffries J, Vasen H, Burn J, Nakken S, Hovig E, Rødland EA, Tharmaratnam K, de Vos Tot Nederveen Cappel WH, Hill J, Wijnen J, Jenkins M, Genuardi M, Green K, Lalloo F, Sunde L, Mints M, Bertario L, Pineda M, Navarro M, Morak M, Frayling IM, Plazzer JP, Sampson JR, Capella G, Möslein G, Mecklin JP, Møller P; Mallorca Group.

Hered Cancer Clin Pract. 2017 Oct 10;15:18. doi: 10.1186/s13053-017-0078-5. eCollection 2017.

5.

Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate.

Ree AH, Russnes HG, Heinrich D, Dueland S, Boye K, Nygaard V, Silwal-Pandit L, Østrup O, Hovig E, Nygaard V, Rødland EA, Nakken S, Øien JT, Johansen C, Bergheim IR, Skarpeteig V, Sathermugathevan M, Sauer T, Lund-Iversen M, Beiske K, Nasser S, Julsrud L, Reisse CH, Ruud EA, Flørenes VA, Hagene KT, Aas E, Lurås H, Johnsen-Soriano S, Geitvik GA, Lingjærde OC, Børresen-Dale AL, Mælandsmo GM, Flatmark K.

ESMO Open. 2017 May 2;2(2):e000158. doi: 10.1136/esmoopen-2017-000158. eCollection 2017.

6.

Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database.

Møller P, Seppälä TT, Bernstein I, Holinski-Feder E, Sala P, Gareth Evans D, Lindblom A, Macrae F, Blanco I, Sijmons RH, Jeffries J, Vasen HFA, Burn J, Nakken S, Hovig E, Rødland EA, Tharmaratnam K, de Vos Tot Nederveen Cappel WH, Hill J, Wijnen JT, Jenkins MA, Green K, Lalloo F, Sunde L, Mints M, Bertario L, Pineda M, Navarro M, Morak M, Renkonen-Sinisalo L, Valentin MD, Frayling IM, Plazzer JP, Pylvanainen K, Genuardi M, Mecklin JP, Moeslein G, Sampson JR, Capella G; Mallorca Group.

Gut. 2018 Jul;67(7):1306-1316. doi: 10.1136/gutjnl-2017-314057. Epub 2017 Jul 28.

7.

Serum N-glycome alterations in breast cancer during multimodal treatment and follow-up.

Saldova R, Haakensen VD, Rødland E, Walsh I, Stöckmann H, Engebraaten O, Børresen-Dale AL, Rudd PM.

Mol Oncol. 2017 Oct;11(10):1361-1379. doi: 10.1002/1878-0261.12105. Epub 2017 Jul 24.

8.

The Longitudinal Transcriptional Response to Neoadjuvant Chemotherapy with and without Bevacizumab in Breast Cancer.

Silwal-Pandit L, Nord S, von der Lippe Gythfeldt H, Møller EK, Fleischer T, Rødland E, Krohn M, Borgen E, Garred Ø, Olsen T, Vu P, Skjerven H, Fangberget A, Holmen MM, Schlitchting E, Wille E, Nordberg Stokke M, Moen Vollan HK, Kristensen V, Langerød A, Lundgren S, Wist E, Naume B, Lingjærde OC, Børresen-Dale AL, Engebraaten O.

Clin Cancer Res. 2017 Aug 15;23(16):4662-4670. doi: 10.1158/1078-0432.CCR-17-0160. Epub 2017 May 9.

9.

Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome.

Aure MR, Vitelli V, Jernström S, Kumar S, Krohn M, Due EU, Haukaas TH, Leivonen SK, Vollan HK, Lüders T, Rødland E, Vaske CJ, Zhao W, Møller EK, Nord S, Giskeødegård GF, Bathen TF, Caldas C, Tramm T, Alsner J, Overgaard J, Geisler J, Bukholm IR, Naume B, Schlichting E, Sauer T, Mills GB, Kåresen R, Mælandsmo GM, Lingjærde OC, Frigessi A, Kristensen VN, Børresen-Dale AL, Sahlberg KK; OSBREAC.

Breast Cancer Res. 2017 Mar 29;19(1):44. doi: 10.1186/s13058-017-0812-y.

10.

Reply to Towfic and others' letter to the editor.

Nygaard V, Rødland EA, Hovig E.

Biostatistics. 2017 Jul 1;18(3):586-587. doi: 10.1093/biostatistics/kxx001. No abstract available.

PMID:
28334081
11.

Incidence of and survival after subsequent cancers in carriers of pathogenic MMR variants with previous cancer: a report from the prospective Lynch syndrome database.

Møller P, Seppälä T, Bernstein I, Holinski-Feder E, Sala P, Evans DG, Lindblom A, Macrae F, Blanco I, Sijmons R, Jeffries J, Vasen H, Burn J, Nakken S, Hovig E, Rødland EA, Tharmaratnam K, de Vos Tot Nederveen Cappel WH, Hill J, Wijnen J, Jenkins M, Green K, Lalloo F, Sunde L, Mints M, Bertario L, Pineda M, Navarro M, Morak M, Renkonen-Sinisalo L, Frayling IM, Plazzer JP, Pylvanainen K, Genuardi M, Mecklin JP, Möslein G, Sampson JR, Capella G; Mallorca Group (http://mallorca-group.org).

Gut. 2017 Sep;66(9):1657-1664. doi: 10.1136/gutjnl-2016-311403. Epub 2016 Jun 3.

12.

Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database.

Møller P, Seppälä T, Bernstein I, Holinski-Feder E, Sala P, Evans DG, Lindblom A, Macrae F, Blanco I, Sijmons R, Jeffries J, Vasen H, Burn J, Nakken S, Hovig E, Rødland EA, Tharmaratnam K, de Vos Tot Nederveen Cappel WH, Hill J, Wijnen J, Green K, Lalloo F, Sunde L, Mints M, Bertario L, Pineda M, Navarro M, Morak M, Renkonen-Sinisalo L, Frayling IM, Plazzer JP, Pylvanainen K, Sampson JR, Capella G, Mecklin JP, Möslein G; Mallorca Group (http://mallorca-group.eu).

Gut. 2017 Mar;66(3):464-472. doi: 10.1136/gutjnl-2015-309675. Epub 2015 Dec 9.

13.

Methods that remove batch effects while retaining group differences may lead to exaggerated confidence in downstream analyses.

Nygaard V, Rødland EA, Hovig E.

Biostatistics. 2016 Jan;17(1):29-39. doi: 10.1093/biostatistics/kxv027. Epub 2015 Aug 13.

14.

Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer.

Aure MR, Jernström S, Krohn M, Vollan HK, Due EU, Rødland E, Kåresen R; Oslo Breast Cancer Research Consortium (OSBREAC), Ram P, Lu Y, Mills GB, Sahlberg KK, Børresen-Dale AL, Lingjærde OC, Kristensen VN.

Genome Med. 2015 Feb 2;7(1):21. doi: 10.1186/s13073-015-0135-5. eCollection 2015.

15.

Molecular subtyping for clinically defined breast cancer subgroups.

Zhao X, Rødland EA, Tibshirani R, Plevritis S.

Breast Cancer Res. 2015 Feb 26;17:29. doi: 10.1186/s13058-015-0520-4.

16.

A statistical model of ChIA-PET data for accurate detection of chromatin 3D interactions.

Paulsen J, Rødland EA, Holden L, Holden M, Hovig E.

Nucleic Acids Res. 2014 Oct;42(18):e143. doi: 10.1093/nar/gku738. Epub 2014 Aug 11.

17.

Systematic assessment of prognostic gene signatures for breast cancer shows distinct influence of time and ER status.

Zhao X, Rødland EA, Sørlie T, Vollan HK, Russnes HG, Kristensen VN, Lingjærde OC, Børresen-Dale AL.

BMC Cancer. 2014 Mar 19;14:211. doi: 10.1186/1471-2407-14-211.

18.

Interplay of choline metabolites and genes in patient-derived breast cancer xenografts.

Grinde MT, Skrbo N, Moestue SA, Rødland EA, Borgan E, Kristian A, Sitter B, Bathen TF, Børresen-Dale AL, Mælandsmo GM, Engebraaten O, Sørlie T, Marangoni E, Gribbestad IS.

Breast Cancer Res. 2014 Jan 21;16(1):R5. doi: 10.1186/bcr3597.

19.

Compact representation of k-mer de Bruijn graphs for genome read assembly.

Rødland EA.

BMC Bioinformatics. 2013 Oct 23;14:313. doi: 10.1186/1471-2105-14-313.

20.

Predicting physical interactions between protein complexes.

Clancy T, Rødland EA, Nygard S, Hovig E.

Mol Cell Proteomics. 2013 Jun;12(6):1723-34. doi: 10.1074/mcp.O112.019828. Epub 2013 Feb 25.

21.

Systemic biomarkers of inflammation and haemostasis in patients with chronic necrotizing pulmonary aspergillosis.

Rødland EK, Ueland T, Bjørnsen S, Sagen EL, Dahl CP, Naalsund A, Mollnes TE, Brosstad FR, Müller F, Aukrust P, Frøland SS.

BMC Infect Dis. 2012 Jun 25;12:144.

22.

Combining gene signatures improves prediction of breast cancer survival.

Zhao X, Rødland EA, Sørlie T, Naume B, Langerød A, Frigessi A, Kristensen VN, Børresen-Dale AL, Lingjærde OC.

PLoS One. 2011 Mar 10;6(3):e17845. doi: 10.1371/journal.pone.0017845.

23.

miRNA-mRNA integrated analysis reveals roles for miRNAs in primary breast tumors.

Enerly E, Steinfeld I, Kleivi K, Leivonen SK, Aure MR, Russnes HG, Rønneberg JA, Johnsen H, Navon R, Rødland E, Mäkelä R, Naume B, Perälä M, Kallioniemi O, Kristensen VN, Yakhini Z, Børresen-Dale AL.

PLoS One. 2011 Feb 22;6(2):e16915. doi: 10.1371/journal.pone.0016915.

24.

Toll like receptor 5 (TLR5) may be involved in the immunological response to Aspergillus fumigatus in vitro.

Rødland EK, Ager-Wick E, Halvorsen B, Müller F, Frøland SS.

Med Mycol. 2011 May;49(4):375-9. doi: 10.3109/13693786.2010.531772. Epub 2010 Nov 10.

PMID:
21067314
25.

Impact of DNA physical properties on local sequence bias of human mutation.

Nakken S, Rødland EA, Hovig E.

Hum Mutat. 2010 Dec;31(12):1316-25. doi: 10.1002/humu.21371. Epub 2010 Nov 16.

PMID:
20886615
26.

The importance of gene-centring microarray data.

Sørlie T, Borgan E, Myhre S, Vollan HK, Russnes H, Zhao X, Nilsen G, Lingjaerde OC, Børresen-Dale AL, Rødland E.

Lancet Oncol. 2010 Aug;11(8):719-20; author reply 720-1. doi: 10.1016/S1470-2045(10)70174-1. No abstract available.

PMID:
20688275
27.

Unstable DNA repair genes shaped by their own sequence modifying phenotypes.

Falster DS, Nakken S, Bergem-Ohr M, Rødland EA, Breivik J.

J Mol Evol. 2010 Mar;70(3):266-74. doi: 10.1007/s00239-010-9328-0. Epub 2010 Mar 6.

28.

Activation of platelets by Aspergillus fumigatus and potential role of platelets in the immunopathogenesis of Aspergillosis.

Rødland EK, Ueland T, Pedersen TM, Halvorsen B, Muller F, Aukrust P, Frøland SS.

Infect Immun. 2010 Mar;78(3):1269-75. doi: 10.1128/IAI.01091-09. Epub 2009 Dec 14.

29.

Characterization of the major formamidopyrimidine-DNA glycosylase homolog in Mycobacterium tuberculosis and its linkage to variable tandem repeats.

Olsen I, Balasingham SV, Davidsen T, Debebe E, Rødland EA, van Soolingen D, Kremer K, Alseth I, Tønjum T.

FEMS Immunol Med Microbiol. 2009 Jul;56(2):151-61. doi: 10.1111/j.1574-695X.2009.00562.x. Epub 2009 Jun 3.

30.

Predicting helix-helix interactions from residue contacts in membrane proteins.

Lo A, Chiu YY, Rødland EA, Lyu PC, Sung TY, Hsu WL.

Bioinformatics. 2009 Apr 15;25(8):996-1003. doi: 10.1093/bioinformatics/btp114. Epub 2009 Feb 25.

31.

Large-scale inference of the point mutational spectrum in human segmental duplications.

Nakken S, Rødland EA, Rognes T, Hovig E.

BMC Genomics. 2009 Jan 22;10:43. doi: 10.1186/1471-2164-10-43.

32.

Expression of genes in normal human monocytes in response to Aspergillus fumigatus.

Rødland EK, Mattingsdal M, Olstad OK, Ovstebø R, Kierulf P, Muller F, Frøland SS.

Med Mycol. 2008 Jun;46(4):327-36. doi: 10.1080/13693780701874507.

PMID:
18415839
33.

Genetic interactions of DNA repair pathways in the pathogen Neisseria meningitidis.

Davidsen T, Tuven HK, Bjørås M, Rødland EA, Tønjum T.

J Bacteriol. 2007 Aug;189(15):5728-37. Epub 2007 May 18.

34.

RNAmmer: consistent and rapid annotation of ribosomal RNA genes.

Lagesen K, Hallin P, Rødland EA, Staerfeldt HH, Rognes T, Ussery DW.

Nucleic Acids Res. 2007;35(9):3100-8. Epub 2007 Apr 22.

35.

DNA repair profiles of disease-associated isolates of Neisseria meningitidis.

Davidsen T, Amundsen EK, Rødland EA, Tønjum T.

FEMS Immunol Med Microbiol. 2007 Mar;49(2):243-51. Epub 2007 Jan 26.

36.

Pseudoknots in RNA secondary structures: representation, enumeration, and prevalence.

Rødland EA.

J Comput Biol. 2006 Jul-Aug;13(6):1197-213.

PMID:
16901237
37.

Biased distribution of DNA uptake sequences towards genome maintenance genes.

Davidsen T, Rødland EA, Lagesen K, Seeberg E, Rognes T, Tønjum T.

Nucleic Acids Res. 2004 Feb 11;32(3):1050-8. Print 2004.

38.

An experimental study on effects of occlusion of the cystic duct in mice with or without emptying of the gallbladder.

Trondsen E, Rosseland AR, Clausen OP, Bakka A, Engh E, Rødland EA, Aasen AO.

Eur Surg Res. 1997;29(2):150-8.

PMID:
9058083
39.

A method for determining the size of internal pilot studies.

Sandvik L, Erikssen J, Mowinckel P, Rødland EA.

Stat Med. 1996 Jul 30;15(14):1587-90.

PMID:
8855484
40.

[Problems when swallowing tablets. A questionnaire study from general practice].

Andersen O, Zweidorff OK, Hjelde T, Rødland EA.

Tidsskr Nor Laegeforen. 1995 Mar 20;115(8):947-9. Norwegian.

PMID:
7709385

Supplemental Content

Loading ...
Support Center